摘要
目的对近年来抗2型糖尿病药物二肽基肽酶Ⅳ(DPP-4)抑制剂的最新研究进展进行综述。方法介绍了已上市和处于临床的药物最新情况,并根据化学结构不同,对处于临床前研究的小分子DPP-4抑制剂进行归纳汇总。结果根据文献查阅,已进入市场的DPP-4抑制剂有12种,处于临床研究阶段的有4个药品,此外有许多新型小分子DPP-4抑制剂处于临床前研究阶段。结论相较于传统药物,新型的DPP-4抑制剂具有疗效好,副作用少,不易诱发低血糖等各种优势,因此开发更安全高效的DPP-4抑制剂具有很大的发展前景。
Objective To comprehend the recent progress of dipeptidyl peptidase IV( DPP-4) inhibitors for anti-type 2 diabetes mellitus,w e w ere review ed. Methods The DPP-4 inhibitors in marketed and in clinical trials w ere introduced. And many small molecule DPP-4 inhibitors in preclinical studies w ere summarized according to the chemical structures. Results There w ere 12 DPP-4 inhibitors that entered the market,4 drugs w ere in the clinical study,and many novel small molecule DPP-4 inhibitors w ere in the preclinical research according to the literature review. Conclusion Compared w ith the traditional drugs,the novel DPP-4 inhibitors have many advantages including good curative effect,few side effects,and lessen hypoglycemia.Therefore,the development of safer and efficient DPP-4 inhibitors has a promising future.
作者
熊丽娟
金一
房元英
XIONG Lijuan;JIN Yi;FANG Yuanying(College of Medicine,Jiangxi University of Traditional Chinese Medicine,Nanchang 330004,China)
出处
《沈阳药科大学学报》
CAS
CSCD
北大核心
2020年第2期181-192,共12页
Journal of Shenyang Pharmaceutical University
基金
国家自然科学基金资助项目(81460526).
关键词
抗2型糖尿病
DPP-4抑制剂
临床研究
anti-type 2 diabetes mellitus
dipeptidyl peptidase IV inhibitors
clinical research
